



wherein: X is a linker selected from the group consisting of C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₃-C₆ alkynylene, wherein X may optionally include 1 or 2 oxygen atoms and/or 1 sulfur atom;

Y is a group pendant from X, wherein Y is a C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, aromatic or cyclic-aliphatic group to which is attached at least one -OSO₃R⁴ moiety, and, optionally, at least one OH group, wherein R⁴ is H or a pharmaceutically acceptable cation; or,

Y is -OSO₃R⁴, wherein R⁴ is H or a pharmaceutically acceptable cation;

N is an integer from 1-3; and

R¹ and R² are each independently selected from the group consisting of -H, a halogen with an atomic number from 9 to 53, hydroxy, -SO₃R⁴, -OSO₃R⁴, -NCS, -NCO, -NH(CO)-OR³, -NH(CS)SR³, -NH(C=NH)OR³, -NHCOCH₂Cl, -NHCOCH₂Br, -NHCO-CH=CH₂, -NHC(O)-CF₃, -S-CH₂-CH=CH₂, -NHCH₂-C≡CH, -NH-CH₂-CN, -NH-S-CH₂-CH=CH₂, -O-CH₂-CH=CH₂, -NH-CF₃, N-mono-, di-, tri-, tetra- and penta-haloethyl, -CN, -NH₂, -NO₂, -NHCOCH₃, -CHO, -COOR⁴, -N₃, -COR³, -R³OH, -R³NHCOCH₃, -R³OSO₃R⁴, -R³SO₃R⁴, -OR³, -SR³ and -R³, wherein -R³ is p-nitrophenyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl, if at the distal end of the substituent, or C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₂-C₆ alkynylene, if at the proximal end of the substituent, and wherein R⁴ is H or a pharmaceutically acceptable cation.

Please cancel claims 1-27 and 40 without prejudice or disclaimer.

REMARKS

Claims 1-40 are pending in this application. Claims 1-27 and 40 have been withdrawn from consideration as being drawn to a non-elected invention. Claims 28-39 are rejected. By